The Plasma Proteins Market in the United States – 2020 provides historical sales in units and dollars of all the therapeutic plasma-derived proteins sold in the United States for the full 2020 year by company, as well the sales of recombinant factors and non-factor products. Early events in 2021 are also profiled. It has been published every year since 1974 in June, and has historical data for growth comparisons along with extensive historical commentary to place the current market in the proper context in this large and complex market. It also analyzes recent developments regarding plasma supply (US plasma collections totals and by company) and fractionation, product distribution and new therapeutic plasma proteins. The companies fractionating plasma and selling products in the United States are profiled.

The report is delivered electronically (Excel and pdf files).

 


 

THE PLASMA PROTEINS MARKET
IN THE UNITED STATES — 2020

 

TABLE OF CONTENTS

Page

 

1

 

16

57

75

111

111

126

160

183

250

257

274

280

284

292

306

 

 

 

EXECUTIVE SUMMARY

 

1) PLASMA COLLECTIONS

2) PLASMA FRACTIONATION

3) MARKET OVERVIEW

4) IMMUNE GLOBULIN MARKET

4.1) HYPERIMMUNE GLOBULINS

4.2) IVIG & SCIG MARKETS

5) ALBUMIN MARKET

6) HEMOPHILIA CARE MARKET

7) PROTHROMBIN COMPLEX (PCC)

8) ALPHA-1 ANTITRYPSIN MARKET (AAT)

9) C-1 ESTERASE INHIBITOR MARKET (C1-INH)

10) ANTITHROMBIN III AND PROTEIN C MARKETS

11) FIBRIN SEALANT AND BIOSURGERY MARKET

12) DISTRIBUTION OF PLASMA PRODUCTS

13) PROFILES OF THE MAJOR COMPANIES